Galectin‐3 and CD44v6 positivity by RT‐PCR method in fine needle aspirates of benign thyroid lesions

Objective:  To investigate whether the presence of macrophages and Hürthle cells (HC) in benign thyroid lesions could explain the false‐positive expression of galectin‐3 and CD44v6 detected by reverse transcriptase‐polymerase chain reaction (RT‐PCR).

[1]  J. Collet,et al.  Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples , 2005, British Journal of Cancer.

[2]  L. Mills,et al.  Galectin‐3 is not useful in thyroid FNA , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[3]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[4]  E. Kimura,et al.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[5]  Y. Vaishnav,et al.  Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  M. Niedziela,et al.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  F. Negro,et al.  Galectin‐3, a marker of well‐differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia , 2002, Histopathology.

[8]  A. Longatto-Filho,et al.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.

[9]  L. Niskanen,et al.  Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma , 2000, The Journal of pathology.

[10]  A. Bartolazzi.  Improving accuracy of cytology for nodular thyroid lesions , 2000, The Lancet.

[11]  S. Natsugoe,et al.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.

[12]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Filetti,et al.  Genetic Analysis in Fine-needle Aspiration of the Thyroid: A New Tool for the Clinic , 1999, Trends in Endocrinology & Metabolism.

[14]  A. Raz,et al.  Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. , 1999, Cancer research.

[15]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[16]  A. Miyauchi,et al.  Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[18]  K. Kashima,et al.  Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells , 1998, Pathology international.

[19]  S. Filetti,et al.  Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  E. Campo,et al.  GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.

[21]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[22]  J. Chabot,et al.  Detection of circulating thyroid cells in peripheral blood. , 1996, Surgery.

[23]  J. Figge,et al.  Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. , 1995, Cancer research.

[24]  L. Xerri,et al.  Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. , 1995, Archives of dermatology.

[25]  S. Barondes,et al.  Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.

[26]  H. Gharib,et al.  Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. , 1994, Mayo Clinic proceedings.

[27]  P. Walfish,et al.  Influence of fine-needle aspiration biopsy and frozen section examination on the management of thyroid cancer. , 1993, American journal of surgery.

[28]  H. Gharib,et al.  Fine-Needle Aspiration Biopsy of the Thyroid: An Appraisal , 1993, Annals of Internal Medicine.

[29]  L. Frigeri,et al.  Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages. , 1992, Journal of immunology.

[30]  S. Pillai,et al.  Molecular cloning of a human macrophage lectin specific for galactose. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[32]  O. Greisen,et al.  Fine-Needle Aspiration Biopsy of the Thyroid Gland , 1984, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[33]  N. Napalkov.  Tumours of the thyroid gland. , 1976, IARC scientific publications.

[34]  T. Hänichen,et al.  Tumours of the thyroid gland. , 1979, Bulletin of the World Health Organization.